COVID-19 vaccine in multiple sclerosis patients treated with disease-modifying therapies: a systematic review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
COVID-19 vaccine in multiple sclerosis patients treated with disease-modifying therapies: a systematic review ; volume:82 ; number:S 01 ; year:2024 ; 01
Konferenz: 25th BCTRIMS Annual Meeting; 2024-06-05; Tivoli Mofarrej São Paulo - SP
Arquivos de neuro-psiquiatria ; 82, Heft S 01 (2024), 01
- Contributor
-
Ripari, Vitória Alagia
Miranda, Maria Constancio
Duarte, Aline Cristina da Silva
Ramos, Déborah Schulthais
- DOI
-
10.1055/s-0044-1789378
- URN
-
urn:nbn:de:101:1-2412121011489.400430331294
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ripari, Vitória Alagia
- Miranda, Maria Constancio
- Duarte, Aline Cristina da Silva
- Ramos, Déborah Schulthais
Other Objects (12)
Current Disease-Modifying Therapies in Multiple Sclerosis
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
Patients experiences with multiple sclerosis disease-modifying therapies in daily life – a qualitative interview study
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Evaluation and further development of handbooks explaining different disease-modifying therapies for people with multiple sclerosis (MS)
Current Disease-Modifying Therapies in Multiple Sclerosis
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
Patients experiences with multiple sclerosis disease-modifying therapies in daily life – a qualitative interview study
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Evaluation and further development of handbooks explaining different disease-modifying therapies for people with multiple sclerosis (MS)
Current Disease-Modifying Therapies in Multiple Sclerosis
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
Patients experiences with multiple sclerosis disease-modifying therapies in daily life – a qualitative interview study
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies